<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39380802</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1188-4169</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Canada communicable disease report = Releve des maladies transmissibles au Canada</Title><ISOAbbreviation>Can Commun Dis Rep</ISOAbbreviation></Journal><ArticleTitle>An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>364</EndPage><MedlinePgn>357-364</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14745/ccdr.v50i10a04</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">As the COVID-19 pandemic unfolded, hundreds of investigational COVID-19 therapeutics emerged. Maintaining situational awareness of this extensive and rapidly evolving therapeutic landscape represented an unprecedented challenge for the Public Health Agency of Canada, as it worked to promote and protect the health of Canadians. A tool to triage and prioritize the assessment of these therapeutics was needed.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The objective was to develop and conduct an initial validation of a tool to identify investigational COVID-19 therapeutics for further review based on an efficient preliminary assessment, using a systematic and reliable process that would be practical to validate, implement and update. Phase 1 of this pilot project consisted of a literature search to identify existing COVID-19 therapeutic assessment prioritization tools, development of the Rapid Scoring Tool (RST) and initial validation of the tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">No tools designed to rank investigational COVID-19 therapeutics for the purpose of prioritizing their assessment were identified. However, a few publications provided criteria to consider and therapeutic ranking methods, which helped shape the development of the RST. The RST included eight criteria and several descriptors ("characteristics"). A universal characteristic scoring scale from -10 to 10 was developed. The sum of all the characteristic scores yielded an overall benefit score for each therapeutic. The RST appropriately ranked therapeutics using a systematic, reliable and practical approach.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Phase 1 was successfully completed. The RST presents several distinct aspects compared with other tools, including its scoring scale and method, and capacity to factor in incomplete or pending information. It is anticipated that the framework used for the RST will lend itself to use in other dynamic situations involving many interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Béïque</LastName><ForeName>Lizanne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Savannah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azad</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarwar</LastName><ForeName>Elaha</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gale-Rowe</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabourin</LastName><ForeName>Stacy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinsky</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arthur</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Commun Dis Rep</MedlineTA><NlmUniqueID>9303729</NlmUniqueID><ISSNLinking>1188-4169</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">decision support techniques</Keyword><Keyword MajorTopicYN="N">investigational therapeutics</Keyword><Keyword MajorTopicYN="N">prioritization</Keyword><Keyword MajorTopicYN="N">therapeutic evaluation</Keyword></KeywordList><CoiStatement>Competing interests None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380802</ArticleId><ArticleId IdType="pmc">PMC11460842</ArticleId><ArticleId IdType="doi">10.14745/ccdr.v50i10a04</ArticleId><ArticleId IdType="pii">501004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ledford H. Hundreds of COVID trials could provide a deluge of new drugs. Nature 2022;603(7899):25–7. 10.1038/d41586-022-00562-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00562-0</ArticleId><ArticleId IdType="pubmed">35233098</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Agency of Canada. 2021-2022 Departmental Results Report. Ottawa, ON: PHAC; 2022 [Accessed 2023 Oct 20]. https://www.canada.ca/en/public-health/corporate/transparency/corporate-management-reporting/departmental-performance-reports/2021-2022.html</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Developing and updating local formularies. Manchester, UK: NICE; 2015. [Accessed 2023 Jul 18]. www.nice.org.uk/Guidance/MPG1</Citation></Reference><Reference><Citation>Esba LC, Almodaimegh H, Alhammad A, Ferwana M, Yousef C, Ismail S. P&amp;T Committee Drug Prioritization Criteria: A Tool Developed by a Saudi Health Care System. P&amp;T
2018;43(5):293–300. https://pubmed.ncbi.nlm.nih.gov/29719371
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5912247</ArticleId><ArticleId IdType="pubmed">29719371</ArticleId></ArticleIdList></Reference><Reference><Citation>Frutos Pérez-Surio A, Gimeno-Gracia M, Alcácera López MA, Sagredo Samanes MA, Pardo Jario MD, Salvador Gómez MD. Systematic review for the development of a pharmaceutical and medical products prioritization framework. J Pharm Policy Pract 2019;12:21. 10.1186/s40545-019-0181-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-019-0181-2</ArticleId><ArticleId IdType="pmc">PMC6702737</ArticleId><ArticleId IdType="pubmed">31452901</ArticleId></ArticleIdList></Reference><Reference><Citation>Husereau D, Boucher M, Noorani H. Priority setting for health technology assessment at CADTH. Int J Technol Assess Health Care 2010;26(3):341–7. 10.1017/S0266462310000383</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462310000383</ArticleId><ArticleId IdType="pubmed">20584365</ArticleId></ArticleIdList></Reference><Reference><Citation>Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion. Drugs 1997;53(4):550–62. 10.2165/00003495-199753040-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-199753040-00002</ArticleId><ArticleId IdType="pubmed">9098659</ArticleId></ArticleIdList></Reference><Reference><Citation>Specchia ML, Favale M, Di Nardo F, Rotundo G, Favaretti C, Ricciardi W, de Waure C; HTA Working Group of the Italian Society of Hygiene, Preventive Medicine and Public Health (SItI) . How to choose health technologies to be assessed by HTA? A review of criteria for priority setting. Epidemiol Prev 2015;39(4 Suppl 1):39–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">26499414</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim FS, Sayan M, Sanlidag T, Uzun B, Ozsahin DU, Ozsahin I. Comparative Evaluation of the Treatment of COVID-19 with Multicriteria Decision-Making Techniques. J Healthc Eng 2021;2021:8864522. 10.1155/2021/8864522</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8864522</ArticleId><ArticleId IdType="pmc">PMC7831275</ArticleId><ArticleId IdType="pubmed">33552457</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung S, Kim S, Kim J, Sohn K. Use of multiattribute utility theory for formulary management in a health system. Am J Health Syst Pharm 2010;67(2):128–35. 10.2146/ajhp080672</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp080672</ArticleId><ArticleId IdType="pubmed">20065267</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs. Front Public Health 2016;4:214. 10.3389/fpubh.2016.00214</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2016.00214</ArticleId><ArticleId IdType="pmc">PMC5042964</ArticleId><ArticleId IdType="pubmed">27747207</ArticleId></ArticleIdList></Reference><Reference><Citation>Oortwijn WJ, Vondeling H, van Barneveld T, van Vugt C, Bouter LM. Priority setting for health technology assessment in The Netherlands: principles and practice. Health Policy 2002;62(3):227–42. 10.1016/S0168-8510(02)00037-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8510(02)00037-4</ArticleId><ArticleId IdType="pubmed">12385849</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, Lönngren T, Mussen F, Peacock S, Watkins J, Devlin N; ISPOR Task Force . Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016;19(2):125–37. 10.1016/j.jval.2015.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.12.016</ArticleId><ArticleId IdType="pubmed">27021745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, Peacock S, Watkins J, Ijzerman M. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016;19(1):1–13. 10.1016/j.jval.2015.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.12.003</ArticleId><ArticleId IdType="pubmed">26797229</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: impact on DEcisionMaking--the EVIDEM framework and potential applications. BMC Health Serv Res 2008;8:270. 10.1186/1472-6963-8-270</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-8-270</ArticleId><ArticleId IdType="pmc">PMC2673218</ArticleId><ArticleId IdType="pubmed">19102752</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making 2012;32(2):376–88. 10.1177/0272989X11416870</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X11416870</ArticleId><ArticleId IdType="pubmed">21987539</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier L, Vandenplas Y, Boone N, Huys I, Janknegt R, Vulto AG. How to select a best-value biological medicine? A practical model to support hospital pharmacists [PubMed]. Am J Health Syst Pharm 2022;79(22):2001–11. 10.1093/ajhp/zxac235</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/zxac235</ArticleId><ArticleId IdType="pmc">PMC9452170</ArticleId><ArticleId IdType="pubmed">36002245</ArticleId></ArticleIdList></Reference><Reference><Citation>Janknegt R, Kooistra J, Metting E, Dekhuijzen R. Rational selection of inhalation devices in the treatment of chronic obstructive pulmonary disease by means of the System of Objectified Judgement Analysis (SOJA). Eur J Hosp Pharm 2021;28(2):e4. 10.1136/ejhpharm-2020-002229</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ejhpharm-2020-002229</ArticleId><ArticleId IdType="pmc">PMC7907694</ArticleId><ArticleId IdType="pubmed">32920532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim TM, Ibrahim MI. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool. Pharm Pract (Granada) 2012;10(3):136–42. 10.4321/S1886-36552012000300003</Citation><ArticleIdList><ArticleId IdType="doi">10.4321/S1886-36552012000300003</ArticleId><ArticleId IdType="pmc">PMC3780493</ArticleId><ArticleId IdType="pubmed">24155829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu JC, Lin JY, Lin PC, Lee YC. Comprehensive value assessment of drugs using a multi-criteria decision analysis: an example of targeted therapies for metastatic colorectal cancer treatment. PLoS One 2019;14(12):e0225938. 10.1371/journal.pone.0225938</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0225938</ArticleId><ArticleId IdType="pmc">PMC6907782</ArticleId><ArticleId IdType="pubmed">31830075</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelis A, Kanavos P. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Soc Sci Med 2017;188:137–56. 10.1016/j.socscimed.2017.06.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2017.06.024</ArticleId><ArticleId IdType="pubmed">28772164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>